Evidence map›Paper›PMID 32322670›Full record

ArticleMolecular therapy oncolytics2020

RBFOX1 Regulates the Permeability of the Blood-Tumor Barrier via the LINC00673/MAFF Pathway.

Shuyuan Shen, Chunqing Yang, Xiaobai Liu, Jian Zheng, Yunhui Liu, Libo Liu, Jun Ma, Teng Ma, Ping An, Yang Lin and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy oncolytics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. A review of linc00673 as a novel lncRNA for tumor regulation.International journal of medical sciences · 2021
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Shuyuan ShenDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang 110122, People's Republic of China.
Chunqing YangDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
Xiaobai LiuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
Jian ZhengDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
Yunhui LiuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
Libo LiuDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang 110122, People's Republic of China.
Jun MaDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang 110122, People's Republic of China.
Teng MaDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang 110122, People's Republic of China.
Ping AnDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang 110122, People's Republic of China.
Yang LinDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang 110122, People's Republic of China.
Heng CaiDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
Di WangDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
Zhen LiDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
Lini ZhaoDepartment of Pharmacology, Shenyang Medical College, Shenyang 110034, People's Republic of China.
Yixue XueDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang 110122, People's Republic of China.
China Medical University · CNShenyang Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The blood-tumor barrier limits the delivery of therapeutic drugs to brain tumor tissues. Selectively opening the blood-tumor barrier is considered crucial for effective chemotherapy of glioma. RNA-binding proteins have emerged as crucial regulators in various biologic processes. This study found that RNA-binding Fox-1 homolog 1 (RBFOX1) was downregulated in glioma vascular endothelial cells derived from glioma tissues, and in glioma endothelial cells obtained by co-culturing endothelial cells with glioma cells. Overexpression of RBFOX1 impaired the integrity of the blood-tumor barrier and increased its permeability. Additionally, RBFOX1 overexpression decreased the expression of tight junction proteins ZO-1, occludin, and claudin-5. Subsequent analysis of the mechanism indicated that the overexpression of RBFOX1 increased musculoaponeurotic fibrosarcoma protein basic leucine zipper [bZIP] transcription factor F (MAFF) expression by downregulating LINC00673, which stabilized MAFF messenger RNA (mRNA) through Staufen1-mediated mRNA decay. Moreover, MAFF could bind to the promoter region and inhibit the promoter activities of ZO-1, occludin, and claudin-5, which reduced its expression. The combination of RBFOX1 upregulation and LINC00673 downregulation promoted doxorubicin delivery across the blood-tumor barrier, resulting in apoptosis of glioma cells. In conclusion, this study indicated that overexpression of RBFOX1 increased blood-tumor barrier permeability through the LINC00673/MAFF pathway, which might provide a new useful target for future enhancement of blood-tumor barrier permeability.

Indexed as

blood-tumor barriergliomaLINC00673MAFFRBFOX1stabilitySTAU1

Identifiers

PMID32322670
PMCPMC7163051
OpenAlexW3014322452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.